Hormone therapy and breast cancer: risk communication and the ‘perfect storm’

References

• Writing Group for the WHI investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Brown S. Shock, terror and controversy: how the media reacted to the Women’s Health Initiative. Climacteric 2012;15:275–80
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Langer RD, Manson JE, Allison M. Have we come full circle – or moved forward? The Women’s Health Initiative 10 years on. Climacteric 2012;15:206–12
   PubMed Web of Science ®Google Scholar
• Langer RD. The evidence for HRT: what can we believe? Climacteric 2017;20:91–86
   PubMed Web of Science ®Google Scholar
• Atkin CK, Smith SW, McFeters C, et al. A comprehensive analysis of breast cancer news coverage in leading media outlets focusing on environmental risks and prevention. J Health Comm 2008;13:3–19
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Egan KM, et al. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 2008;168:404–11
   PubMed Web of Science ®Google Scholar
• Dewdney AK. 200% of Nothing: From “Percentage Pumping” to “Irrational Ratios”: An Eye-Opening Tour Through the Twists and Turns of Math Abuse and Innumeracy. New York: John Wiley & Sons Inc; 1993
   Google Scholar
• Bluming AZ, Tavris C. What are the real risks for breast cancer? Climacteric 2012;15:133–8
   PubMed Web of Science ®Google Scholar
• Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping doctors and patients make sense of health statistics. Psychol Sci Publ Interest 2007;8:53–96
   PubMedGoogle Scholar
• Gotzsche PC. Time to stop mammography screening? CMAJ 2011;183:1957
   PubMed Web of Science ®Google Scholar
• Autier P, Boniol M, Middleton R, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011;22:1726–35.
   PubMed Web of Science ®Google Scholar
• Independent UK Panel. The benefits and harms of breast screening: an independent review. Lancet 2012;380:1778
   PubMed Web of Science ®Google Scholar
• Amir E, Bedard PL, Ocana A, et al. Benefits and harms of detecting clinically occult breast cancer. J Natl Cancer Inst 2012;104:1542–47
   PubMed Web of Science ®Google Scholar
• Wegwarth O, Schwartz LM, Woloshin S, et al. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med 2012;156:340–9
   PubMed Web of Science ®Google Scholar
• O’Donoghue C, Esserman L. Recognizing the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer 2013;108:2200–1
   PubMed Web of Science ®Google Scholar
• Carles M, Martinez-Alonso M, Pons A, et al. The effect of information about the benefits and harms of mammography on women’s decision-making: study protocol for a randomized controlled trial. Trials 2017;18:426
   PubMedGoogle Scholar
• Darby SC, Ewertz M, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98
   PubMed Web of Science ®Google Scholar
• Henson KE, McGale P, Taylor C, et al. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 2013;108:179–82
   PubMed Web of Science ®Google Scholar
• Omarini C, Thanopoulou E, Johnston SRD. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat 2014;146:245–58
   PubMed Web of Science ®Google Scholar
• Welch HG, Frankel BA. Likelihood that a woman with screen-detected breast cancer has had her “life saved” by that screening. Arch Intern Med 2011;171:2043–6
   PubMedGoogle Scholar
• Raffle AE, Gray JAM. Screening: Evidence and Practice. Oxford: Oxford University Press; 2007:1–288
   Google Scholar
• Larson RJ, Woloshin S, Schwartz LM, Welch HG. Celebrity endorsements of cancer screening. J Natl Cancer Inst 2005;97:693–5
   PubMed Web of Science ®Google Scholar
• King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy. Minneapolis (MN): University of Minnesota Press; 2006
   Google Scholar
• Hart PL. Women’s perception of coronary heart disease: an integrative review. J Cardiovasc Nursing 2005;20:170–6
   PubMedGoogle Scholar
• Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med 2003;348:1672–80
   PubMed Web of Science ®Google Scholar
• Nedrow A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006;166:1453–65
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Grigoriadis S, et al. Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 2005;172:57–9
   PubMed Web of Science ®Google Scholar
• Sarri G, Pedder H, Dias S, et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG 2017;124:1514–23
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Vulvovaginal atrophy: a tale of neglect. Climacteric 2014;17:1–2
   Web of Science ®Google Scholar
• Gallagher JC, Levine JP. Preventing osteoporosis in symptomatic postmenopausal women. Menopause 2011;18:109–18
   PubMed Web of Science ®Google Scholar
• Islam S, Liu Q, Chines A, et al. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009;16:77–83
   PubMed Web of Science ®Google Scholar
• Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Climacteric 2017;20:402–13
   PubMed Web of Science ®Google Scholar